Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seelos Therapeutics, Inc. - Common Stock (NQ:SEEL)

1.280 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seelos Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
Psychedelic Stock Gainers And Losers From December 21, 2022
 
Via Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 19, 2022
 
Via Benzinga
Major Psychedelic Drug Stocks Down Another 7% This Week; Now Down 54% YTD
The 6 largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances are down again this week. 
Via Talk Markets
Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Parkinson's Study Using CRISPR Technology Shows Promise, Seelos Therapeutics Says
 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 14, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 13, 2022
 
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 12, 2022
 
Via Benzinga
Major Psychedelic Drug Stocks DOWN 9% Last Week; Now Down 51% YTD
Today's article highlights the performance of the largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From December 9, 2022
 
Via Benzinga
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 7, 2022
 
Via Benzinga
Seelos Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today
 
Via Benzinga
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
 
Via Benzinga
Major Psychedelic Drug Stocks Went Up 7% This Week; Still Down 46% YTD
The 6 major psychedelic stocks researching the treatment of a variety of mental illnesses were UP 7% this week and are UP 3 % in the last 6 weeks. The 6 therapy clinic stocks went UP 3% this week and... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From December 2, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 1, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 30, 2022
 
Via Benzinga
Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today
 
Via Benzinga
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
 
Via Benzinga
Cannabis Category Performances Last Week Ranged From +5.2% To -2.3%
The 5 categories in the cannabis sector perform quite differently week to week and last week was no exception. This article is a summary of how each category performed last week, in descending order... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From November 25, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 24, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 23, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 22, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 21, 2022
 
Via Benzinga
Psychedelic Drug Stocks Index Continued To Decline Last Week
This article highlights the performances of the 6 constituents in the munKNEE Psychedelic Drug Stocks Index last week and in the last 3 weeks and the extent to which each company is likely to encounter... 
Via Talk Markets
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.